Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259511 | 1.00 | TDP1 (0.42) | TDP1AOC3CYP2C19SMN1; SMN2FFAR1 | |
| SCHEMBL4416823 | 0.91 | SLC6A2 (0.37) | TDP1AOC3CYP2C19SMN1; SMN2FFAR1 | |
| SCHEMBL4414784 | 0.91 | SLC6A2 (0.37) | TDP1AOC3CYP2C19SMN1; SMN2FFAR1 | |
| SCHEMBL4265627 | 0.87 | TDP1 (0.43) | TDP1AOC3SMN1; SMN2FFAR1RIPK1 | |
| SCHEMBL4262564 | 0.87 | TDP1 (0.43) | TDP1AOC3SMN1; SMN2FFAR1RIPK1 | |
| SCHEMBL4261669 | 0.80 | TACR1 (0.36) | AOC3 | |
| SCHEMBL4256188 | 0.80 | TACR1 (0.36) | TDP1AOC3SMN1; SMN2 | |
| SCHEMBL4258143 | 0.78 | TACR1 (0.56) | — | |
| SCHEMBL21551717 | 0.76 | GABBR2 (0.39) | AOC3CYP2C19SMN1; SMN2GABBR2GABBR1 | |
| SCHEMBL6002205 | 0.76 | TACR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20060172988-A1 | Azetidine compounds | ALBIREO AB (SE) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172988-A1 | Azetidine compounds | HRH2, HRH4, HRH1 | TDP1 4143/4885AOC3 23/4885CYP2C19 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.